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For a health problem or condition to be considered a pub-
lic health issue, four criteria must be met: 1) the health
condition must place a large burden on society, a burden
that is getting larger despite existing control efforts; 2) the
burden must be distributed unfairly (i.e., certain segments
of the population are unequally affected); 3) there must be
evidence that upstream preventive strategies could sub-
stantially reduce the burden of the condition; and 4) such
preventive strategies are not yet in place. Chronic kidney
disease meets these criteria for a public health issue.
Therefore, as a complement to clinical approaches to con-
trolling it, a broad and coordinated public health approach
will be necessary to meet the burgeoning health, economic,
and societal challenges of chronic kidney disease.
Chronic Kidney Disease: A Public Health
Problem?
Health problems or conditions become public health
issues when four criteria are met (1,2). First, the disease
burden is high (i.e., it affects many people, has increased
recently, and will likely increase in the future). This bur-
den is experienced in terms of mortality and morbidity,
quality of life, and cost and is perceived as a threat by the
public; that is, there is a sense of fear that the disease is
out of control. Second, the problem is distributed unfairly
(i.e., it does not affect all people the same but affects
minorities and disadvantaged individuals to a greater
extent). Third, there is evidence that upstream preventive
strategies — strategies that target economic, political, and
environmental factors that affect a population’s health —
could substantially reduce the burden of the condition; and
fourth, evidence shows that such preventive strategies are
not yet in place.
Chronic kidney disease (CKD) meets these criteria for
consideration as a public health issue. For the first criteri-
on, there are now more than 385,000 people in the United
States with end-stage renal disease (ESRD) (3), the form of
CKD in which life can be sustained only by dialysis or
transplantation. Milder forms of CKD that do not yet
require renal replacement therapy are even more common
than ESRD. The total number of Americans living with
CKD is now estimated to be 19.2 million, representing 11%
of the adult U.S. population; the 0.22% of the population
estimated to have ESRD (4) comes from this large group of
individuals with early CKD.
The burden of CKD is growing. During the past three
decades, the incidence and prevalence of ESRD have risen
progressively. For example, annual new cases of ESRD
increased from approximately 14,500 in 1978 to 100,359 in
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2002; during the same period, the number of individuals
on dialysis and with kidney transplants increased from
42,000 to 431,000 (3,5). Estimates for 1993 to 1995 were
that 2% of white men, 1.7% of white women, 5.5% of black
men, and 6.3% of black women would develop ESRD dur-
ing their lifetime (6). Five years later, however, these esti-
mates had increased to 2.5% of white men, 1.8% of white
women, 7.3% of black men, and 7.8% of black women (7).
Projections to the year 2010 estimate an annual 4.1%
increase in incident ESRD cases, although recent data
from the U.S. Renal Data System (USRDS) indicate that
the rate of increase is lessening (5,8). By 2030, it is esti-
mated that the annual number of people with new onset of
ESRD will exceed 450,000, and those receiving dialysis or
who have had kidney transplants will exceed 2 million (9).
CKD causes premature morbidity and mortality and
lowers quality of life; it is also expensive. Yearly death
rates of ESRD patients are approximately 20%. CKD
patients have a risk of cardiovascular disease (CVD) that
is 10 to 30 times that of people without kidney disease (10).
Recently, data from several large, diverse populations
have shown that progressive decreases in the glomerular
filtration rate (GFR) were associated with increased risks
of death, cardiovascular events, and hospitalization; these
risks were fewer than those reported in ESRD patients
(11,12). Deaths caused by CKD were estimated at 71,000
in 2000 and are expected to increase to 352,000 in 2030 (9).
Recently, using data from death certificates, the Centers
for Disease Control and Prevention (CDC) listed kidney
disease as the ninth leading cause of death in the United
States (13). However, this statistic underestimates the
burden of kidney disease because it does not reflect the
high rates of comorbidity in the CKD population. Indeed,
CKD patients have a greater likelihood of dying from
comorbidities of kidney disease than of progressing to
ESRD (14,15). In addition to reducing lifespan, CKD sub-
stantially reduces quality of life, and yet it is often not rec-
ognized as a serious health problem in the United States.
Treating ESRD imposes a large economic burden on
patients, the health care system, and society. Although
people with kidney failure represent less than 1% of the
Medicare population (individuals with kidney failure,
regardless of age, are eligible for Medicare funding), their
care consumes 6.4% of the health care expenditures by the
Centers for Medicare and Medicaid Services. In 2001, total
expenditures (Medicare plus private payers) exceeded $22
billion, of which approximately two thirds was provided by
Medicare (5). In addition, recent data from a large HMO
and from the USRDS indicate that the total health care
resources used for CKD patients are 1.6 to 2.4 times (or
more) those resources used by the ESRD population (16).
The fact that one in nine Americans is estimated to have
CKD and another 20 million are at risk for developing it
has resulted in fear that the disease is out of control.
CKD also meets the second criterion of a public health
issue: it disproportionately affects racial and ethnic
minorities, among whom worse outcomes and higher costs
of treatment are common. African Americans and
American Indians are at especially increased risk (17).
International data suggest that CKD is a worldwide public
health problem (17). Age alone is a key predictor of CKD,
and 11% of people in the United States aged 65 years or
older (without diabetes or hypertension) have moderately
to severely decreased kidney function (4). Currently dia-
betes is the most common cause of kidney failure, now
accounting for nearly one half of new cases of ESRD, and
by 2006 it is expected to surpass all other causes of new
cases combined (i.e., hypertension, glomerulonephritis,
and others) (9).
The third and fourth criteria are also satisfied by CKD:
it is feasible to act on the condition at the community and
public health levels. Despite the tremendous burden of
CKD, there is good news — we have the requisite knowl-
edge to prevent or at least delay its onset, its progression,
and the comorbidities that accompany it. Upstream pre-
ventive strategies are not yet in place but if implemented
effectively could reduce the burden of CKD.
Potential for Prevention of CKD
Fortunately, the large burden of CKD does not appear to
be inevitable; there are many reasons to believe it can be
reduced substantially. A key will be the early identification
of individuals who are at risk. There is evidence that earli-
er stages of CKD can be detected and treated and that
adverse outcomes of CKD can be prevented or delayed (17).
Clinical diagnosis of CKD has become simplified. The
most sensitive test for early CKD is urine albumin. The
earliest stage of low-grade albumin leakage into urine is
called  microalbuminuria. Current recommendations call
for annual urine testing of people with diabetes (18-20).
Although recommendations for testing for other risk
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at least with simple dipstick methods, has been calculat-
ed to be cost effective in people with hypertension (21).
Also, the GFR (the major kidney function test) can be rea-
sonably estimated from serum creatinine using an equa-
tion validated in a large number of subjects with CKD in
combination with the variables of age, sex, and race (18).
Thus, a determination of serum creatinine level and a spot
urine sample for albumin–creatinine ratio are sufficient to
detect CKD.
Current preventive care practices include maintaining
stringent control of blood pressure to a target of 130/80 mm
Hg, using angiotensin-converting enzyme inhibitors
(ACEIs) and angiotensin II receptor blockers (ARBs) in
both diabetic and nondiabetic nephropathies, maintaining
careful glycemic control in individuals with diabetes, and
following a low-protein diet (21). Additional reports indi-
cate that treating dyslipidemia, losing weight, quitting
smoking, and managing anemia may also help to delay
progression of early CKD; however, some of these results
must be tempered by the fact that relatively few patients
were enrolled in these studies (21,22).
The benefits of treating early kidney disease may extend
beyond the kidney itself. Indeed, a recent publication indi-
cated that in the general population, the presence of albu-
minuria (a key indicator of kidney disease) predicted both
cardiovascular and noncardiovascular mortality (23). It
has been suggested that in many cases, microalbuminuria
is simply the renal manifestation of a generalized abnor-
mality of vascular function (24). A recent report showed
that using fosinopril (an ACEI) to treat individuals who
were identified from screening as having microalbumin-
uria led to a reduction in both albuminuria and cardiovas-
cular events (25), the latter the major cause of death in
patients with CKD (10). However, these results were
obtained from a relatively small sample size with lack of
statistical significance of the cardiovascular events, so con-
firmatory results from a larger trial are needed.
Several studies have demonstrated the potential for pre-
venting or delaying the initial onset of diabetic kidney dis-
ease by treating patients who have diabetes with ACEIs.
ACEIs prevent the development of microalbuminuria. In
the early stages of diabetes, patients may have heightened
renal function, which manifests itself as a high GFR, some-
times called hyperfiltration. Such a state may precede the
development of microalbuminuria in diabetes (21).
Unfortunately, many patients with CKD still receive
suboptimal care (26-28). The disease is both underdiag-
nosed and undertreated. The reasons for this subopti-
mal care are likely complex, but people at risk because
of diabetes or hypertension are often unaware that
CKD can be caused by these conditions. In addition,
screening with quantitative urinary albumin measure-
ments is inadequately performed in patients with dia-
betes. Also, the usual clinical index of kidney function,
the serum creatinine concentration, is often poorly
interpreted by clinicians.
A Public Health Problem That Needs a
Public Health Approach
CKD is not being detected early enough to initiate
treatment regimens and reduce death and disability
(17). In addition, many interventions are being delivered
too late to improve population-based outcomes. Finally,
most individuals with CKD are unaware that they have
this disorder (17,29). Thus, the issue of CKD extends
beyond a clinical problem addressed only by health care
providers to a major public health issue requiring multi-
level efforts. Initiatives should be undertaken to make
health care providers and the general population more
aware of the seriousness of CKD, its risk factors, and
opportunities for screening. People identified with CKD
should be provided appropriate educational materials to
explain the treatment regimens and the benefits of
undertaking therapy. We must work with health care
delivery organizations to ensure access to high-quality
care, and we must provide data and information to health
care policy makers so that their decisions will effectively
address CKD.
The USRDS collects, analyzes, and distributes informa-
tion on ESRD patients (3,5). Currently, however, there is
no data surveillance system for tracking patients with
CKD in stages before dialysis or transplantation, unless
they are aged 65 years or older and covered by Medicare
(and thus can be tracked by the Centers for Medicare and
Medicaid Services). CDC has a national surveillance sys-
tem in place for diabetes (available from www.cdc.gov/
diabetes), and there are national surveillance efforts with
the Behavioral Risk Factor Surveillance System (BRFSS),
National Health and Nutrition Examination Survey
(NHANES), National Health Interview Survey (NHIS),
and National Hospital Discharge Survey (NHDS), among
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others, to assess cardiovascular disease. However, data are
scant for CKD. Clearly, to get a better understanding of
the nature and extent of the CKD burden and to inform
policy decisions, national surveillance data on this disorder
need to be made available.
Additional public health efforts to address CKD are
sorely needed, but some important first steps have been
taken. These include publication of clinical practice
guidelines for CKD by the National Kidney
Foundation–Kidney Disease Outcomes Quality
Initiative (NKF–K/DOQI) (17), a meeting of stakehold-
ers to assess priorities (30), and the establishment of the
National Kidney Disease Education Program (NKDEP)
(31). Sponsored by the National Institute of Diabetes and
Digestive and Kidney Diseases, NKDEP was created to
reduce morbidity and mortality from kidney disease and
its complications. Through public education and system-
level initiatives such as improving the reporting by clin-
ical laboratories of kidney function, NKDEP aims to
raise awareness that kidney disease is serious, that it is
important to test people at risk, and that treatment is
available to prevent entirely or slow the progression of
the disease (31).
Several additional elements are needed to address CKD
effectively. A comprehensive effort will require patient
education, professional education, and the involvement of
payers (Medicare, Medicaid, and the health insurance
industry). In addition, the involvement or cooperation of
business, the community, and government will be
required; national, state, and local initiatives will all be
needed. More research efforts will be needed to measure
and track the CKD burden, identify populations at risk,
and target program efforts.
Conclusion
The burden of CKD, in terms of human suffering and
economic costs, is exploding as we move through the
early years of the 21st century, making it a major pub-
lic health issue. We know how to prevent or delay the
onset of CKD and to limit its progression.
Unfortunately, the extent to which we have applied this
knowledge, which can effectively reduce the burden of
CKD, is disappointing. A comprehensive public health
approach will be needed to effectively address this
major health problem.
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